Boston Scientific Q3 2026: Cyberattack Drives Sales Drop, Investor Confidence Tests
Boston Scientific’s Q3 2026 earnings fell 23% after a cyberattack that hit manufacturing, but the firm’s robust medical‑device portfolio still drives demand and investors watch its cyber‑security rebuild.
2 minutes to read